Jazz Pharmaceuticals plc (J7Z) — Capital Reinvestment Ratio
Jazz Pharmaceuticals plc (J7Z) has a Capital Reinvestment Ratio of 0.05x as of March 2026, meaning it reinvests 0% of its operating cash flow (€408.20 Million) in capital expenditures (€19.70 Million). Check J7Z goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Jazz Pharmaceuticals plc Capital Reinvestment Ratio (2013–2025)
This chart tracks Jazz Pharmaceuticals plc's Capital Reinvestment Ratio across 13 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Jazz Pharmaceuticals plc.
Annual Capital Reinvestment Ratio for Jazz Pharmaceuticals plc (2013–2025)
Year-by-year Capital Reinvestment Ratio for Jazz Pharmaceuticals plc from 2013 to 2025. See cash generation quality of Jazz Pharmaceuticals plc to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.15x | €1.36 Billion | €209.75 Million | ▲ +349.3% |
| 2024 | 0.03x | €1.40 Billion | €48.07 Million | ▼ -12.5% |
| 2023 | 0.04x | €1.09 Billion | €42.96 Million | ▲ +72.3% |
| 2022 | 0.02x | €1.27 Billion | €29.05 Million | ▼ -35.7% |
| 2021 | 0.04x | €778.51 Million | €27.64 Million | ▲ +112.9% |
| 2020 | 0.02x | €899.65 Million | €15.00 Million | ▼ -67.7% |
| 2019 | 0.05x | €776.40 Million | €40.13 Million | ▲ +102.7% |
| 2018 | 0.03x | €798.90 Million | €20.37 Million | ▼ -39.0% |
| 2017 | 0.04x | €693.09 Million | €28.95 Million | ▼ -86.4% |
| 2016 | 0.31x | €592.39 Million | €181.58 Million | ▲ +353.5% |
| 2015 | 0.07x | €531.94 Million | €35.96 Million | ▼ -24.2% |
| 2014 | 0.09x | €407.61 Million | €36.35 Million | ▲ +157.8% |
| 2013 | 0.03x | €288.43 Million | €9.98 Million | — |